DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2013; 138(20): 1073-1076DOI: 10.1055/s-0033-1343111 Kommentar | Commentary Pathologie, Onkologie © Georg Thieme Verlag KG Stuttgart · New York Klinische Studien in der Onkologie: eine Herausforderung für die klinische und akademische Pathologie Clinical studies in oncology – a challenge for clinical and academic pathology C. Röcken 1 Institut für Pathologie der Universität Kiel › Author Affiliations Recommend Article Abstract Buy Article Schlüsselwörter Schlüsselwörterpersonalisierte Therapie - molekulare Marker - zielgerichtete Tumortherapie - klinische Studien - Pathologie - Companion Diagnostics Keywords Keywordspersonalized treatment - molecular markers - targeted tumor therapy - clinical research - pathology - companion diagnostics Full Text References Literatur 1 Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA). Lancet 2010; 376: 687-697 2 Bossuyt PM, Reitsma JB, Bruns DE et al. Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am J Clin Pathol 2003; 119: 18-22 3 Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes – a systematic review. Int J Cancer 2012; 130: 2845-2856 4 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 5 Herpel E, Röcken C, Manke H et al. Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Arch 2010; 457: 741-747 6 Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805 7 Jörgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer. J Cancer 2012; 3: 137-144 8 Lordick F, Röcken C. The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. Ann Oncol 2013; Mar 19. [Epub ahead of print] 9 Manke H, Röcken C. Accreditation in pathology. Pathologe 2008; 29: 388-402 10 McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072 11 Rüschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307 12 Verband Forschender Arzneimittelhersteller (VFA). Entwicklungsprojekte für innovative Arzneimittel Bessere Medikamente in Sicht: Perspektive 2015. http://www.vfa.de/de/arzneimittel-forschung/woran-wir-forschen/bessere-medikamente-in-sicht-perspektive-2015.html/_1/_2/_3/_4 (letzter Zugriff 11.4.2013) 13 Verband Forschender Arzneimittelhersteller (VFA). In Deutschland zugelassene Arzneimittel für die personalisierte Medizin. http://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/individualisierte-medizin.html (letzter Zugriff 11.4.2013)
